Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies

Deepa Manwani¹ and Paul S. Frenette²,³,⁴

Departments of ¹ Pediatrics and ² Medicine, and ³ Cell Biology ⁴ Ruth L. and David S Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, New York, USA
Abstract

Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management as well as prevention of these events utilizing the fetal hemoglobin reactivating agent, hydroxyurea, are currently the mainstay of treatment. Discoveries over the last two decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.

Introduction

Sickle cell disease (SCD) results from a single amino acid substitution in the gene encoding the β-globin subunit. Polymerization of deoxygenated sickle hemoglobin leads to decreased deformability of red blood cells (RBCs). Via a complex interplay of adhesive events among blood cells, these altered erythrocytes can obstruct the vasculature, producing episodes of pain, hemolytic anemia, organ injury and early mortality. Although the molecular basis of SCD is well characterized, the complex mechanisms underlying vaso-occlusion (VOC) have not been fully elucidated. Early studies using in vitro adhesion assays or a rat mesocecum ex vivo perfusion model uncovered the role of sickle RBCs (SS-RBCs) in initiating and propagating the vaso-occlusive events via adhesive interactions with the endothelium. Preferential adhesion of low density SS-RBCs and reticulocytes in immediate post-capillary venules, leads to trapping of the older, more dense, and misshapen SS-RBCs, resulting in reduced blood flow. Random precapillary obstruction by a small number of dense SS-RBCs also contributed to VOC. More recent data indicate that other blood cell elements, not directly affected by the sickle cell mutation, play a direct role in VOC. A new model has been proposed in which the process is viewed as multistep and multicellular cascade driven by inflammatory stimuli and the adherence of leukocytes.

Sickle RBCs are prone to adhere

Sickle hemoglobin can cause damage to the RBC membrane from deformation by polymer formation. In addition, the mutated globin can undergo auto-oxidation, and precipitate on the inner surface of the RBC membrane, causing membrane damage via iron-mediated generation of oxidants. Amongst the many changes that result from the damage to the SS-RBC membrane is their propensity to adhere. Some of the adhesion molecules on the surface of the SS-RBCs (e.g. α4β1) have been reported to interact directly with the endothelial cell membrane (e.g. VCAM-1) without the participation of an intervening plasma protein. Other adhesive interactions require a soluble bridge molecule (e.g. thrombospondin, vWF). SS-RBC adhesion molecules (e.g, BCAM/LU, α4β1) have also been reported to interact with the sub-endothelial matrix proteins (e.g, laminin, vWF). SS-RBC interactions with the vascular endothelium may lead to the production of oxygen radicals by the endothelial cell and oxidant-dependent activation of the transcription factor NF-κB. NF-κB upregulates the transcription of various genes, including adhesion molecules such as E-selectin, VCAM-1, ICAM-1, on the surface of the endothelium. Circulating endothelial cells characterized by an activated phenotype (expression of VCAM-1 and E-selectin) and increased levels of plasma sVCAM-1 have also been reported, reflective of continuous endothelial activation. Both endothelial selectins, P- and E-selectin, have been suggested to participate in VOC. An anti-P-selectin aptamer in SCD mice resulted in a decreased adhesion of SS-RBCs, increased microvascular flow velocities and reduced adhesion of the leukocyte to the endothelium, underscoring the importance of P-selectin as a potential therapeutic target. The blood group glycoprotein LW (also called ICAM-4) is an RBC adhesion receptor that can be activated by epinephrine to mediate SS-RBC adhesion to endothelial αvβ3 integrin. In a sickle cell murine model, these interactions led to VOC and also increased leukocyte adhesion to endothelium. Propranolol (a β-adrenergic receptor antagonist) and
recombinant LW infusions were shown to inhibit the VOC, supporting the events noted in patients that report a painful crisis precipitated by emotional stress or physical exertion. Interestingly, signals from the sympathetic nervous system transmitted by β-adrenergic receptors can also mediate circadian oscillations of leukocyte recruitment in tissues that impact the inflammatory response. Adrenergic control of leukocyte trafficking produces higher densities of adherent leukocytes in venules at night time in mice. SCD mice indeed exhibit a more dramatic vaso-occlusive phenotype when the experiment is carried out at night time. Diurnal differences of admission to the hospital of SCD patient in vaso-occlusive crisis have been reported although the gradual onset of vaso-occlusive crisis renders circadian influences difficult to discern.

**Sickle RBCs promote inflammation**

The damaged SS-RBCs and activated endothelial cells can produce a pro-inflammatory environment that is exacerbated during episodes of crisis. Circulating leukocytes and platelets also have an activated phenotype. Ischemia-reperfusion injury, release of free hemoglobin and heme secondary to RBC lysis and increased production of placental growth factor (PIGF) may contribute to the inflammatory vasculopathy. Levels of PIGF, an angiogenic growth factor produced by erythroblasts, are elevated in the plasma of individuals with SCD. Monocytes from SCD patients are activated in response to PIGF, secreting increased levels of tumor necrosis factor (TNF-α), interleukin-1 and other chemokines.

Ischemia-reperfusion injury secondary to ongoing, intermittent microvascular occlusions promote chronic inflammation in SCD by increased oxidant production, increased adhesion of leukocytes to the endothelium followed by extravasation into the tissues and finally damage to the tissues. The inflammatory cascade from ischemia-reperfusion is amplified by the activation of CD1d-restricted iNKT cells. Compared with controls, SCD mice have more numerous and activated (CD69+, interferon-γ+ [IFN-γ+]) lung, liver, and spleen iNKT cells that are hyper responsive to hypoxia/reoxygenation. SCD mice have increased pulmonary levels of IFN-γ+, IFN-γ-inducible chemokines (CXCL9, CXCL10), and increased number of lymphocytes expressing the chemokine receptor CXCR3. Treatment of SCD mice with anti-CD1d antibody to inhibit iNKT cell activation or treatment with CXCR3 inhibitors reverses pulmonary dysfunction. Like mice, patients with SCD have increased numbers of activated circulating iNKT cells expressing CXCR3, suggesting that iNKT cells may play a critical role in mediating inflammation.

Intravascular hemolysis results in release of cell free hemoglobin in the plasma, translocation of hemoglobin to the spaces between the endothelium and the smooth muscle cells, nitric oxide depletion in the plasma and subendothelial spaces, oxidative stress, and hemin release that contribute to the inflammation. Hemin binds to the transcriptional repressor Bach-1, which regulates transcription of heme-oxygenase and other anti-oxidant enzymes essential for the adaptive response to enhanced intracellular hemin levels.

The chronic inflammatory milieu in SCD activates coagulation. Abnormal phosphatidylserine exposure on the surface of the sickle RBCs and RBC- and platelet-derived microparticles drives thrombin generation. Inflammation and hemolysis promotes increased expression of tissue factor (TF), a primary activator of the extrinsic pathway of coagulation. Tissue factor, however, also enhances inflammation and contributes to endothelial cell injury. Reduction of plasma levels of TF in a sickle cell transgenic mouse model results in decreased plasma levels of IL-6 and soluble VCAM-1. Circulating platelets in SCD patients are chronically activated and express higher levels of P-selectin, CD40 ligand and the pro-inflammatory cytokine TNFSF14. Thus activation of coagulation is not just a secondary event contributing to increased thrombo-embolic events, but also drives inflammation and vascular injury. An interplay of all these processes perpetuates and feeds forward an inflammatory priming that, in the presence of a “second hit” or precipitating event, can lead to VOC.
Neutrophil adhesion and activation, critical steps for vaso-occlusion

Various studies have noted a surprising pivotal role of neutrophils in a disease caused by a mutation only expressed in the erythroid lineage. Hofstra et al first reported that neutrophils could bind to SS-RBCs in vitro.\textsuperscript{17} In contrast to the previously described interaction with the endothelium, the dense cell fractions that included irreversibly sickled RBCs appeared to be the most adherent to neutrophils. In vivo evidence for this phenomenon was first reported using SCD mice that exclusively express human sickle hemoglobin. To observe dynamic interactions between the vascular wall and flowing blood cells, the cremasteric microvasculature was examined using intravital microscopy\textsuperscript{6} In this model, more striking than the occasional direct interactions of the SS-RBC with the endothelium were the prominent interactions of circulating SS-RBCs with adherent leukocytes. These interactions were increased or sustained after exogenous administration of TNF-\(\alpha\) and frequently resulted in complete VOC. Mice deficient in both P-selectin and E-selectin were unable to recruit leukocytes at the vessel wall and were protected from TNF-\(\alpha\)-induced VOC. This suggested that the recruitment of the adherent leukocytes to activated endothelium was necessary for the vaso-occlusive process.

Heterotypic interactions are regulated by E-selectin and mediated by \(\alpha\)\(_{\text{M}}\)\(\beta\)\(_2\) integrin

Although selectins are best known to mediate rolling interactions allowing leukocyte recruitment to the vessel wall, they are bone fide signaling molecules that can contribute to cell activation beyond the initial events allowing leukocytes to firmly adhere. While both P-selectin and E-selectin are important for adhesion of leukocytes to the endothelium, E-selectin on the endothelium appears crucial for generating a secondary wave of activating signals, which produces a polarized expression of activated \(\alpha\)\(_{\text{M}}\)\(\beta\)\(_2\) integrin (also known as CD11b/CD18 or Mac-1) at the leading edge of the crawling neutrophil, mediating the capture of erythrocytes.\textsuperscript{18} Inhibition of Src family kinases, but not p38 mitogen activated protein kinase (MAPK) or spleen tyrosine kinase (Syk) can reduce RBC capture. Mice deficient in the C3 complement protein, a ligand for Mac-1 integrin, have a partial reduction in RBC capture, suggesting the role of complement opsonization on the RBCs. Surprisingly, inhibition of E-selectin abrogates these effects, whereas inhibition of P-selectin has only a partial effect. E-selectin signaling can trigger “inside-out” \(\alpha\)\(_{\text{M}}\)\(\beta\)\(_2\) activation at the leading edge of the PMNs, whereas in turn, the engagement of platelets by activated \(\alpha\)\(_{\text{M}}\)\(\beta\)\(_2\) can trigger “outside-in” signaling in PMNs leading to production of reactive oxygen species (ROS).\textsuperscript{19} While no significant platelet accumulation has been observed at vaso-occlusive sites in SCD mice (P.S.F., unpublished data), there is indirect evidence for their role in VOC as inhibition of platelet activation both reduces the inflammatory milieu and the formation of platelet-monocyte and platelet-neutrophil aggregates.\textsuperscript{20}

The generation of a novel synthetic pan-selectin inhibitor, GMI-1070, with maximal activity against E-selectin, made it possible to further test this paradigm in VOC. As predicted by the model above, its administration to SCD mice resulted in decreased leukocyte adhesion, increased leukocyte rolling velocity, dramatic reduction of RBC capture by the neutrophils and improved blood flow rates.\textsuperscript{21} GMI-1070 is being evaluated in a Phase II clinical trial whose results are pending at the writing of this manuscript.

Intravenous immunoglobulins modulate neutrophil activation and vascular injury through Fc\(\gamma\)RIII and SHP-1

In SCD mice, intravenous immunoglobulins (IVIG) can reverse acute vaso-occlusive crisis by inhibiting neutrophil adhesion to the endothelium and abrogating SS-RBC capture.\textsuperscript{22,23} Although the low-affinity Fc\(\gamma\)RIIB is crucial for IVIG’s beneficial effect in a murine model of immune thrombocytopenia and other models involving macrophage function\textsuperscript{24}, neutrophils predominantly express the “activating” Fc\(\gamma\)RIII receptor. Indeed, Fc\(\gamma\)RIII, but not Fc\(\gamma\)RIIB, was found to mediate IVIG’s inhibition of leukocyte adhesion, RBC capture and reduced Mac-1 activity via recruitment of Src homology 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1) in
SCD mice. Ongoing Phase I/II randomized double-blind placebo-controlled studies are evaluating the role of IVIG in acute VOC.

**Intravascular hemolysis and vaso-occlusion**

It is possible that severe, acute or sub-acute hemolysis, triggers VOC by overwhelming the adaptive mechanisms. Clinical support for this concept, for example, comes from the observation that delayed hemolytic transfusion reactions can precipitate vaso-occlusive events. Recent studies in a sickle cell murine model of hemolytic transfusion reaction (HTR) have identified CXCL1 as a key inflammatory mediator of VOC. Exogenous administration of CXCL1 was sufficient to induce VOC and inhibition of CXCR2, the receptor for CXCL1, prevented the HTR-induced VOC. Targeted inhibition of this pathway may represent a new therapeutic approach for VOC.

Murine models of SCD support an important role of hemolysis in VOC as well. When infused into sickle cell mice, cell-free hemoglobin and its reactive ferric protoporphyrin-IX group, hemin, produce vascular stasis. This can be inhibited by haptoglobin or hemopexin supplementation or over expression of heme-oxygenase-1 (HO-1).

**Proposed model of sickle cell vaso-occlusion**

Based on direct observations in SCD mice, the following model of VOC is proposed in which adhesive interactions of SS-RBCs and leukocytes to the endothelium play important roles in the initiation of VOC (Figure 1). While the exact mechanisms remain incompletely elucidated, one can speculate that the activated adherent leukocytes which are rigid and larger than SS-RBCs likely drive VOC in collecting venules whereas the SS-RBCs may contribute in smaller vessels or in situations where there isn’t a potent inflammatory trigger. Triggers for VOC vary and can include inflammation, stress, increased viscosity, decreased flow, hemolysis or a combination of factors.

1) Endothelial activation by SS-RBCs and other inflammatory mediators
2) Recruitment of adherent leukocytes
3) Activation of recruited neutrophils and of other leukocytes (e.g. monocytes or iNKT cells)
4) Interactions of sickle erythrocytes with adherent neutrophils
5) Vascular clogging by heterotypic cell-cell aggregates composed of SS-RBCs, adherent leukocytes and possibly platelets
6) Increased transit time to greater than the delay time for deoxygenation-induced hemoglobin polymerization, propagating retrograde vaso-occlusion
7) Ischemia as a result of the obstruction that creates a feedback loop of worsening endothelial activation. The process described above is highly dynamic and can potentially be reversed with targeted therapy.

**Emerging Therapies**

Since polymerization of the abnormal hemoglobin is a key step in the cascade of events described above, it has been an important therapeutic target for over five decades. While fetal hemoglobin inducing agents have had a tremendous impact in decreasing the number and severity of vaso-occlusive episodes, our current understanding provides a compelling argument for clinical trials targeting other cell types and inflammatory processes.
Fetal hemoglobin-inducing agents

**Hydroxyurea** is a potent inducer of fetal hemoglobin (HbF), and evidence over the past 25 years has documented its laboratory and clinical efficacy for both adults and children with SCD.28 Given its indisputable efficacy in responders, current efforts are directed towards expanding utilization in developed and developing nations. Its role as potential standard of care for all patients, starting at a young age will become clearer as more data emerge on prevention of organ damage and genotoxicity with long-term use. While hydroxyurea non-responders are rare in childhood, about a third of adults will not respond, making alternative and combination therapies a worthwhile endeavor. A recent report of co-administration of arginine as a NO substrate in a small group of patients in a randomized trial29 demonstrated an augmented HbF response and highlighted the need for future multi-agent trials. A dose limiting toxicity for hydroxyurea can be myelosuppression.2 novel fetal hemoglobin inducing agents, sodium dimethylbutyrate and pomalidomide are not myelosuppressive and actually stimulate erythropoiesis. Unfortunately combination therapy of hydroxyurea with sodium dimethylbutyrate in a clinical trial and with pomalidomide in a murine model resulted in a blunted HbF response.30

**Decitabine** is a potent HbF inducer that acts via hypomethylation of the γ globin promoter. In small studies thus far, it has produced a 100% response rate, even in patients that previously did not respond to hydroxyurea.33 Ongoing trials will further clarify its efficacy and tolerability. A Phase I combination of study of oral decitabine with tetrahydrouridine, a competitive inhibitor of cytidine deaminase, is targeted at improved oral bioavailability of decitabine.34

- Oral sodium dimethylbutyrate is currently being evaluated in clinical trials.31 Robust HbF responses were documented to intravenous infusions of arginine butyrate, but its short half-life makes it unattractive as a long-term therapy.

Targeting adhesion:

As briefly mentioned above, **GMI-1070** is a pan-selectin antagonist currently under investigation in clinical trials. This randomized double-blind placebo-controlled trial examined the efficacy, safety and pharmacokinetics of GMI-1070, in hospitalized patients with SCD experiencing VOC. GlycoMimetics successfully enrolled 76 patients 12 to 60 years of age at 22 trial sites in the United States and Canada. Results of these studies have not yet been published in a peer-reviewed journal.

**IVIG** also inhibits leukocyte adhesion and activation (Figure 2). Its role in SCD patients with acute VOC is being evaluated in Phase I/II studies via a dose escalation strategy. Currently, the study is recruiting at the 800mg/kg dose level and no significant adverse events have been noted thus far (n=17, D.M. and P.S.F., unpublished observations).

**Tinzaparin**, a low molecular weight heparin, was studied in a randomized double blind clinical trial. Heparins act via inhibition of P-selectin-mediated adhesion35 and other anti-inflammatory effects36, in addition to their expected anticoagulant effect. After exclusion of patients with thrombocytopenia or CNS vasculopathy, 253 subjects were enrolled, ages 12 years and older, in a study in which reduced duration of VOC and no severe bleeding complications were reported.37 These results need to be validated in a multicenter study. An oral P-selectin inhibitor with an order of magnitude greater potency than heparin, demonstrated improved microvascular flow in SCD patients in a Phase I study, but has a very short half-life.35 The
efficacy of SelG1, a humanized anti-P-selectin monoclonal antibody, in preventing VOC will be evaluated in an upcoming Phase II trial.

Propranolol was administered to SCD patients in a Phase I dose escalation study and significantly reduced epinephrine-stimulated SS-RBC adhesion in a dose dependent manner. Adverse events were not severe, did not show dose dependence, and were likely unrelated to drug. These results imply that β-blockers have a potential role as anti-adhesive therapy via inhibition of cAMP mediated inhibition of SS-RBC adhesion, which did not always correlate to areas of leukocyte adhesion. A phase II study of propranolol in SCD is currently open.

Targeting inflammation

Regadenoson is an A2A receptor (A2AR) agonist reported in a phase I study in SCD patients to reduce iNKT cell activation to control levels. The trial was conducted at five participating sites in the United States. No toxicity was noted. Based on positive findings in the biological endpoints, a phase II randomized placebo-controlled trial is currently ongoing. iNKT activation in patients during VOC (n=6) was associated with increased phospho-NF-κB p65 and A2AR expression and also higher IFN-γ levels. Although the reduction in phospho-NF-κB p65 was to baseline levels, the reduction in A2AR expression and IFN-γ levels did not reach baseline.

Anti-oxidant therapy

Omega-3 fatty acids are significantly reduced in SCD patients. A randomized placebo-controlled double-blind trial was conducted at a single center in Sudan. Enrolled patients (n=140) were monitored for a year and Omega-3 treatment reduced VOC events and transfusions. The therapy was well tolerated and warrants further study.

N-Acetyl Cysteine (NAC) inhibits dense cell formation and irreversible sickle cells (ISC) in SS-RBCs in vitro and restores glutathione levels toward normal. ROS are also produced by SS-RBCs and neutrophils during VOC. A phase II double-blind randomized clinical trial was completed to determine the efficacy of NAC in decreasing dense cell and ISC formation, and vaso-occlusive episodes in SCD. Twenty-one subjects at a single center were enrolled in four treatment groups. NAC inhibited dense cell formation, restored glutathione levels toward normal, and decreased VOC episodes at a well-tolerated dose of 2,400 mg per day (n=6). These results need to be validated in a larger, multicenter study.

Anti-platelet therapy

Prasugrel is a novel thienopyridine P2Y12 adenosine diphosphate (ADP) receptor antagonist that inhibits ADP-mediated platelet activation and aggregation. Randomized double-blind placebo-controlled Phase II studies to examine safety were completed in adults. There were no hemorrhagic events requiring medical intervention in either study arm. Mean pain rates (percentage of days with pain) and intensity in the prasugrel arm were decreased compared with placebo. However, these reductions did not reach statistical significance. Platelet surface P-selectin and plasma soluble P-selectin, biomarkers of platelet activation, were significantly reduced in SCD patients receiving prasugrel compared with placebo. Prasugrel was well tolerated and a Phase III trial in children is registered and will be recruiting.

In summary, understanding of the pathophysiology of sickle VOC has led to several new exciting agents that are currently being evaluated. Recruitment in clinical trials and robust endpoints continue to represent significant challenges for translation to the clinic of even single agents. Given the complexity and multiplicity of events leading to the vaso-occlusive event, it is likely that a multi-targeted multi-modal approach will be required to achieve the best outcome. A rigorous attention to design trial, close collaboration between basic scientists and clinicians and a good dose of perseverance will be important in obtaining clear answers as we move forward.
Acknowledgments:

This work was supported in part by the National Institute of Health (R01 grants HL097819, DK056638 and HL116340 to P.S.F.).

Authorship Contributions:

Both authors wrote the manuscript.

Disclosures:

Conflict-of-interest disclosure: The authors declare no competing financial interests. Many important scientific and clinical contributions in sickle cell disease are beyond the scope of this report. We apologize to authors of important contributions that could not be cited owing to space limitations. Off-label drug use: drugs described in research studies are not being recommended for clinical off-label use; the discussion focuses on their experimental effects on the pathophysiology of sickle cell disease.
REFERENCES:


<table>
<thead>
<tr>
<th>Year</th>
<th>Scientific Observation</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1910</td>
<td>James Herrick: Description of the first patient with sickle-shaped RBCs on peripheral smear</td>
<td>Original description</td>
</tr>
<tr>
<td>1930</td>
<td>Shriver and Waugh: Venous circulation in a patient is enriched in sickle-shaped cells that regain normal shape upon reoxygenation</td>
<td>A disease of the RBC</td>
</tr>
<tr>
<td>1949</td>
<td>Linus Pauling demonstrates that the disease originates from a mutated hemoglobin molecule</td>
<td>A molecular disease of hemoglobin</td>
</tr>
<tr>
<td>1974</td>
<td>Hofrichter and Eaton: “delay time” for the initiation of rapid phase of deoxy-HbS polymerisation.</td>
<td>Vaso-occlusion is dependent on deoxy HbS concentration and transit time of the RBCs</td>
</tr>
<tr>
<td>1979, 1980</td>
<td>Hebbel and Hoover: Increased propensity of SS-RBCs to adhere to endothelium in vitro and correlation with disease severity</td>
<td>Widened the scope of scientific studies outside the RBC. Adhesive interactions of the RBCs and endothelium leads to VOC</td>
</tr>
<tr>
<td>1978-1986</td>
<td>Brugnara and others: increased KCl co-transport and Gardos channel activity in SS-RBCs</td>
<td>SS- RBC dehydration due to cation loss</td>
</tr>
<tr>
<td>1989</td>
<td>Kaul and Nagel: SS RBCs adhere in post-capillary venules SS reticulocytes are more adherent than older and denser RBCs.</td>
<td>SS reticulocytes initiate VOC by adhering to endothelium, followed by trapping of dense cells, hypoxia and retrograde extension of obstruction to neighboring vessels.</td>
</tr>
<tr>
<td>1984-2004</td>
<td>Characterization of multiple discrete mechanisms of sickle RBC adhesion</td>
<td>Role of cell, matrix adhesion molecules and plasma factors in VOC</td>
</tr>
<tr>
<td>1994</td>
<td>Platt: Baseline WBC count &gt; 15 x 10^9 / L is associated with increase morbidity and mortality.</td>
<td>Leukocyte counts are a marker of SCD severity</td>
</tr>
<tr>
<td>1997</td>
<td>Pastzy and Narla/Ryan and Townes: Humanized murine models of SCD</td>
<td>Transgenic models expressing only human sickle hemoglobin</td>
</tr>
<tr>
<td>2000</td>
<td>Kaul and Hebbel: exaggerated inflammatory response in hypoxia followed by reoxygenation</td>
<td>Contribution of the ischemia-reperfusion injury to inflammation</td>
</tr>
<tr>
<td>2002</td>
<td>Turhan and Frenette: SS-RBC interactions with adherent leukocytes initiate VOC. P- and E-selectin deficiency protects against TNF-α induced VOC</td>
<td>First in vivo evidence in a sickle cell murine model for the role of leukocytes in initiating VOC. P and E-selectins are important in mediating this interaction.</td>
</tr>
<tr>
<td>2002</td>
<td>Reiter and Gladwin: Cell-free hemoglobin limits nitric oxide bioavailability in SCD</td>
<td>Nitric oxide depletion in SCD and its contribution to vasculopathy</td>
</tr>
<tr>
<td>2003</td>
<td>Hines and Parise: Role for epinephrine in the regulation of BCAM/Lu dependant SS RBC adhesiveness</td>
<td>Role of physiologic stress as a trigger for VOC</td>
</tr>
<tr>
<td>2004-2007</td>
<td>Zennadi and Telen: Epinephrine-induced activation of LW-mediated sickle cell adhesion and VOC in a vivo mouse model is blocked by propranolol</td>
<td>Identifies β-adrenergic receptor antagonism as a potential therapeutic approach</td>
</tr>
<tr>
<td>2009</td>
<td>Wallace and Linden: Ischemia reperfusion injury is amplified by the activation of CD1d-restricted iNKT cells.</td>
<td>Role of iNKT cells in triggering inflammation.</td>
</tr>
<tr>
<td>2009</td>
<td>Hidalgo and Frenette: Role of secondary activation signals in neutrophils</td>
<td>Role of E-selectin as an activating signal, Src kinases and α5β2.</td>
</tr>
<tr>
<td>2009</td>
<td>Belcher and Vercellotti: Heme oxygenase-1 inhibits vascular stasis in a murine model of SCD</td>
<td>Importance of Heme in inflammation and VOC</td>
</tr>
<tr>
<td>Category*</td>
<td>Therapeutic Agent</td>
<td>Mechanism of Action</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>----------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Fetal hemoglobin augmentation</td>
<td>Vorinostat, Panobinostat</td>
<td>HDAC inhibition</td>
</tr>
<tr>
<td></td>
<td>Sodium dimethylbutyrate</td>
<td>HDAC inhibition</td>
</tr>
<tr>
<td></td>
<td>Decitabine</td>
<td>DNA demethylation</td>
</tr>
<tr>
<td></td>
<td>Pomalidomide</td>
<td>Histone acetylation of γ globin promoter</td>
</tr>
<tr>
<td>Adhesion</td>
<td>GMI-1070</td>
<td>Pan-selectin inhibitor</td>
</tr>
<tr>
<td></td>
<td>IVIG</td>
<td>Inhibits neutrophil activation and RBC capture</td>
</tr>
<tr>
<td></td>
<td>SelG1</td>
<td>Humanized anti-P-selectin monoclonal antibody</td>
</tr>
<tr>
<td></td>
<td>Heparin (tinzaparin)</td>
<td>Inhibits P-selectin</td>
</tr>
<tr>
<td></td>
<td>Propranolol</td>
<td>Inhibits RBC adhesion to the endothelium</td>
</tr>
<tr>
<td>Inflammation</td>
<td>Regadenoson</td>
<td>A2AR agonist, blocks iNKT activation</td>
</tr>
<tr>
<td></td>
<td>Statins</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Zileuton</td>
<td>5-lipoxygenase inhibitor, used in asthma</td>
</tr>
<tr>
<td></td>
<td>Fructose-1,6-diphosphate</td>
<td>Reduces ischemia–induced tissue damage</td>
</tr>
<tr>
<td></td>
<td>(FDP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MP4CO</td>
<td>PEG carboxy-hemoglobin</td>
</tr>
<tr>
<td>Anti-platelet therapy</td>
<td>Prasugrel</td>
<td>ADP receptor blockade</td>
</tr>
<tr>
<td></td>
<td>Eptifibatide</td>
<td>αIIb/β3 antagonist</td>
</tr>
<tr>
<td>Oxidative injury</td>
<td>Omega-3 fatty acids</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glutamine</td>
<td>Increases NADPH</td>
</tr>
<tr>
<td></td>
<td>N-acetylcysteine</td>
<td>Increased glutathione</td>
</tr>
<tr>
<td></td>
<td>Alpha-lipoic acid</td>
<td>Inhibits NF-kB, increases glutathione</td>
</tr>
<tr>
<td></td>
<td>Acetyl-L-carnitine</td>
<td>Decreases lipid peroxidation</td>
</tr>
<tr>
<td>Anti-sickling agent</td>
<td>Aes-103</td>
<td>Binds sickle hemoglobin and shifts oxyhemoglobin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dissociation curve to the left</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Poloxamer-188</td>
<td>Non-ionic surfactant, improves microvascular flow</td>
</tr>
<tr>
<td>Vascular tone</td>
<td>Intravenous magnesium</td>
<td>Vasodilation</td>
</tr>
<tr>
<td>NO</td>
<td>L-arginine</td>
<td>Substrate for NO</td>
</tr>
</tbody>
</table>

*Some therapies have multiple mechanisms of action
Figure legends:

Figure 1: Sickle cell vaso-occlusion. SS-RBCs and other inflammatory mediators induce the activation of the endothelium. The damaged and stimulated endothelium is poised to recruit leukocytes. E-selectin on the endothelium is crucial for generating a secondary wave of activating signals, which produces a polarized expression of activated \( \alpha M\beta 2 \) integrin (Mac-1) at the leading edge of the crawling neutrophil, allowing the capture of circulating discoid and sickle shaped erythrocytes. These events culminate in vaso-occlusion in the post-capillary venules.

Figure 2: Activating and inhibitory arms of neutrophil activation. E-selectin-mediated adhesion activates Src kinases which then leads to the upregulation the leukocyte integrin Mac-1 at the leading edge of crawling neutrophils. GMI-1070 works principally by inhibiting E-selectin-mediated activation. Polarized expression of activated Mac-1 allows the capture of erythrocytes. IVIG administration works by binding to FcyRIII expressed on neutrophils, leading to the recruitment of Src homology 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1) that inhibits Mac-1 activation.
Figure 1.
Figure 2.
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies

Deepa Manwani and Paul S. Frenette